It is well known that vascular endothelial growth factors (VEGFs) and their receptors (vascular endothelial growth factor receptors, VEGFRs) are expressed in different tissues, and VEGF-VEGFR loops regulate a wide range of responses, including metabolic homeostasis, cell proliferation, migration and tubuleogenesis. As ligands, VEGFs act on three structurally related VEGFRs (VEGFR1, VEGFR2 and VEGFR3 [also termed FLT1, KDR and FLT4, respectively]) that deliver downstream signals. Haematopoietic stem cells (HSCs), megakaryocytic cell lines, cultured megakaryocytes (MKs), primary MKs and abnormal MKs express and secrete VEGFs. During the development from HSCs to MKs, VEGFR1, VEGFR2 and VEGFR3 are expressed at different developmental stages, respectively, and re-expressed, e.g., VEGFR2, and play different roles in commitment, differentiation, proliferation, survival and polyplodization of HSCs/MKs via autocrine, paracrine and/or even intracrine loops. Moreover, VEGFs and their receptors are abnormally expressed in MKrelated diseases, including myeloproliferative neoplasms, myelodysplastic syndromes and acute megakaryocytic leukaemia (a rare subtype of acute myeloid leukaemia), and they lead to the disordered proliferation/differentiation of bone marrow cells and angiogenesis, indicating that they are closely related to these diseases. Thus, targeting VEGF-VEGFR loops may be of potential therapeutic value.
Background
Vascular endothelial growth factors (VEGFs) are part of a family of conserved disulphide-linked soluble secretory glycoproteins that are found in higher eukaryotes. VEGFs modulate a wide range of responses, including metabolic homeostasis, cell proliferation, migration and tubulogenesis, in different tissues.
These responses are initiated by VEGF binding to soluble and membrane-bound VEGFRs (vascular endothelial growth factor receptors) and co-receptors, including neuropilins (NRPs) and integrins (Koch et al, 2011; Smith et al, 2015) . VEGFs are the major regulators of vascular development as well as blood and lymphatic function in adult health and diseases (Koch et al, 2011) . The VEGF family consists of five structurally related factors: VEGFA (the prototype), VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF, also termed PGF). Although naturally occurring VEGFA and PlGF heterodimers exist, the VEGF family members are mainly homodimeric polypeptides (Koch et al, 2011) . Selective splicing (such as with VEGFA, VEGFB and PlGF) and processing (such as with VEGFA, VEGFC and VEGFD) further increase their complexity (Koch et al, 2011) . For example, VEGFA is selectively spliced to produce VEGFA121, VEGFA145, VEGFA165 and VEGFA189 (numerically indicating the number of amino acid residues in each human polypeptide).
VEGFs function by binding three structurally related VEGF receptor tyrosine kinases, that are made up of an extracellular ligand-binding region with an Ig-like domain, a transmembrane domain, and a TK domain within the cytoplasmic domain, and include VEGFR1 (FLT1), VEGFR2 (KDR, FLK1), and VEGFR3 (FLT4). The binding of VEGFs with VEGFRs leads to phosphorylation in different tyrosine residues in different intracellular domains of different VEGFRs (Fig 1) . These receptors noticeably exhibit overlapping but different expression patterns. Although the overall pattern is that VEGFR1 is expressed in monocytes and macrophages, with VEGFR2 in vascular endothelial cells and VEGFR3 in lymphoid endothelial cells, the expression of VEGF receptors is more extensive than initially predicted (Koch et al, 2011) . For example, VEGFR1 is also expressed on haematopoietic stem cells (HSCs), vascular smooth muscle cells and leukaemic cells (Bellamy et al, 1999; Hattori et al, 2002; Banerjee et al, 2008) , whereas VEGFR2 is expressed on endothelial progenitor cells and megakaryocytes (Gill et al, 2001; Casella et al, 2003) .
Megakaryocytopoiesis
Megakaryocytes (MKs) are derived from HSCs. Thrombopoietin (TPO, THPO), the major regulator of MK development, regulates all stages of megakaryocytopoiesis: for example, the commitment and proliferation of haematopoietic progenitor cells (HPCs), the proliferation of megakaryocytic progenitor (MKP) cells, polyploidization of MK precursors (promegakaryoblasts), and the final maturation, including the formation of membrane demarcations and platelet production (Kaushansky, 1995; Zucker-Franklin & Kaushansky, 1996; Cramer et al, 1997; Zimmet & Ravid, 2000; Bluteau et al, 2009) (Fig 2) . MKs are unique among blood cells in Binding specificity of VEGFs and signalling complexes of VEGFRs with specific tyrosine phosphorylations. Five vascular endothelial growth factors (VEGFA, VEGFB, VEGFC, VEGFD and PlGF) bind to three VEGF receptor tyrosine kinases (VEGFRs) and two neuropilin (NRP) coreceptors with different affinities to initiate the formation of homodimers and heterodimers. The proteolytic processing of VEGFC and VEGFD binds VEGFR2. The extracellular domains of the VEGFRs and NRPs involved in VEGF binding are represented by the hatched circle. The phosphorylation of specific tyrosines at different domains in different homodimers and heterodimers of VEGFR signalling complexes are indicated. CTD, carboxyl-terminal domain; JMD, juxtamembrane domain; KID, kinase insert domain; NRP1/2, neuropilin 1/2; PlGF, placenta growth factor; sVEGFR1/2, soluble VEGFR1/2; TKD1, ATP binding domain; TKD2, phosphotransferase domain; TMD, transmembrane domain; Y, tyrosine. their ability to attain states of high ploidy (up to 256 N) by endomitosis, a process that involves multiple cycles of aborted late anaphase and cytokinesis and the re-entrance into the G1 phase of the higher polyploidy cell cycle (Nagata et al, 1997; Bluteau et al, 2009 (Miyawaki et al, 2017) . Therefore, the expression of CD41 begins at the HPC (mouse) or CMP (human) stage and the expression of CD42b begins at the MKP stage during megakaryocytopoiesis (Woolthuis & Park, 2016) .
Role of VEGFs/VEGFRs in megakaryocytopoiesis
Effect of VEGFs/VEGFRs on the regulation of HSCs
VEGFs are not only well-known factors in angiogenesis, but they also play some important roles in the growth and differentiation of haematopoietic cells. The homozygous or heterozygous deletion of Vegfa (previously termed Vegf) in mice leads to impaired angiogenesis and haematopoiesis, which causes early embryonic lethality (Carmeliet et al, 1996; Ferrara et al, 1996) . Further investigation with the conditional deletion of Vegfa in haematopoietic cells showed that VEGFA is required for the survival and repopulation of adult HSCs (Gerber et al, 2002) . VEGFR1 agonists rescued the survival and repopulation of VEGFA-deficient HSCs in mice, revealing a VEGFR1 signalling during haematopoiesis (Gerber et al, 2002) . VEGFR2 is a positive functional marker defining stem cells (Ziegler et al, 1999 ) that mediate the survival of HPCs through the activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway (Larrivee et al, 2003) . VEGFR2 also mediates the phosphorylation of both STAT3
Fig 2. Effects of VEGFRs on the development of MKs. MK development undergoes a series of processes: the proliferation of HSCs and their commitment to MKPs mainly through MPPs, CMPs and CD41 + CMPs, but partially through CMPs and MEPs; the proliferation of MKPs; the polyploidization of MKs precursors (including PMKLs) and the final maturation (including the formation of membrane demarcations and platelet shedding regulated by TPO). VEGFA is expressed and secreted by HABs, HSCs, MKPs, PMKLs, MKs and platelets. VEGFA in combination with TPO promotes the production of HABs and the differentiation of these HABs into HSCs. PlGF promotes the recruitment of VEGFR1 + HSCs from a quiescent to a proliferative bone marrow microenvironment. VEGFR1 is expressed at very low levels in quiescent HSCs and increases sharply during the initial stages of MK differentiation, followed by a decline in the later stages of maturation. VEGFR2 is also expressed at very low levels in quiescent HSCs; it is rapidly down-modulated after the induction of differentiation, and then re-expressed in advanced MK maturation. The activation of both VEGFR1 and VEGFR2 promotes the polyploidization of MKs. VEGFR3 is expressed on MKPs and early PMKLs, which are referred to as stage I MKs, and are small with single or bi-lobed nuclei occupying almost the entire cell volume (Ma, et al 1996 , Weinstein et al, 1981 . VEGFR3 as a negative regulator plays a role in the polyploidization of the PKML stage. CMPs, common myeloid progenitors; HABs, haemangioblasts; HSCs, haematopoietic stem cells; MEPs, megakaryocyte-erythrocyte progenitors; MKPs, megakaryocytic progenitors; MKs, megakaryocytes; MPPs, multipotent progenitors; PMKLs, promegakaryoblasts; TPO, thrombopoietin; TPO, thrombopoistin; VEGFA, vascular endothelial growth factor A; VEGFR1/2/3, VEGF receptor 1/2/3. and STAT5 by VEGF (Ye et al, 2004) . Furthermore, VEGFA has been shown to be an essential factor for HSC niche formation through endochondral ossification (Chan et al, 2009) , and the conditional deletion of VEGFR2 in adult mice blocked the regeneration of bone marrow (BM) sinusoidal endothelial cells (SECs) in sublethally irradiated animals and prevented haematopoietic reconstitution (Hooper et al, 2009) . It was also shown that VEGFA165 promoted erythropoietic development from human embryonic stem cells (hESCs) and enhanced the in vitro self-renewal potential of primitive haematopoietic cells that are capable of erythroid progenitor capacity (Cerdan et al, 2004) . Moreover, VEGFC was critically required in the transition to fetal erythropoiesis (Fang et al, 2016) . In addition, CD34 + cells in human cord blood can differentiate into VEGFR1 + cells in association with the appearance of monocyte-macrophage markers after induction with haematopoietic cytokines, and the majority of the monocyte-marker CD97 + cell population in human peripheral blood expressed VEGFR1, which mediated the migration of the monocytes that were induced by VEGFA (Hiratsuka et al, 1998; Sawano et al, 2001) . VEGFs also have a potent HSC mobilization capacity. It was shown that acute administration of high doses of VEGFA, when delivered by an adenovirus, promoted the rapid mobilization of HSCs Moore et al, 2001) . PlGF promotes recruitment of VEGFR1 + HSCs from a quiescent to a proliferative BM microenvironment, favouring the differentiation, mobilization and reconstitution of haematopoiesis (Hattori et al, 2002) . Anti-VEGFR1 antibody blocked the mobilization of BM-derived myeloid progenitors in the peripheral blood (Luttun et al, 2002) . However, this mobilization of HSCs by VEGFA appears to be an acute effect Moore et al, 2001) , because the repeated treatment of VEGFA in mice, which stimulates the entry of HPCs into the S/G2/M phase of the cell cycle via binding to VEGFR, might lead to the suppression of the mobilization of HSCs (Pitchford et al, 2009) . Moreover, the acute response may be via VEGFR2-mediated vascular dilation (Lim et al, 2014) , as the anti-VEGFR2 antibody significantly blocked VEGFA165-induced mobilization of leucocytes and colony-forming unit cells to the peripheral circulation ). In addition, the acute administration of high doses of VEGFa that are delivered by an adenovirus, is associated with capillary leakiness, which may facilitate the escape of HPCs from the BM Moore et al, 2001) . Therefore, the acute response is other than a direct effect of VEGFR on HSCs. Noticeably, the chemokine axis SDF-1a (CXCL12)/CXCR4 is critically involved in the retention of HSCs within the BM, and G-CSF has been shown to promote mobilization of haematopoietic progenitor cells by disrupting the SDF-1a/CXCR4 retention axis, both by reducing the CXCR4 expression on HPCs and the levels of SDF-1a in the BM (Levesque et al, 2003) . In contrast, VEGFA treatment abolished HPCs' ability to migrate to SDF-1a although VEGFA did not alter CXCR4 expression on HPCs, suggesting that HPCs from VEGFA-treated mice were refractory to migratory stimuli despite expressing CXCR4. Therefore, other mechanisms could not be ruled out. In addition, human postnatal haemangioblasts (HABs) have been shown to express VEGFR2 (Pelosi et al, 2002 ) and a combination of TPO and VEGFA could significantly increase the number of HABs produced by rhesus monkey ESCs, and could even promote differentiation of these HABs into CD34
+ HSCs (Wang et al, 2005) . (Fig 2) .
Role of VEGFs/VEGFRs in the development of MKs
Expression of VEGFs/VEGFRs in MKs. In 1995, it was found that the KDR gene transcript, which encodes VEGFR2 (KDR) protein, and the VEGFA gene transcript were expressed on MKs, platelets and human leukaemia cell lines (HEL and CMK86) (Katoh et al, 1995) . Subsequently, a series of in vivo and in vitro studies have shown that VEGFs and/or VEGFRs were expressed in megakaryocytic cell lines, such as HEL, CMK86 and Dami (Katoh et al, 1995; Mohle et al, 1997; Maloney et al, 1998; Bonsi et al, 2005; Thiele et al, 2012) , in vitro cultured MKs (Mohle et al, 1997; Casella et al, 2003) and primary MKs (Katoh et al, 1995; Banks et al, 1998; Bellamy, 2001; Ghannadan et al, 2003; Krauth et al, 2004; Wimazal et al, 2006; Sugiyama et al, 2010) . It has been reported that large quantities of VEGFA were detected in the supernatant of cultured MK cell line cells (CMK, Dami and HEL), and MKs (CD41a + ) that were generated by the ex vivo expansion of HSCs, and primary MKs that were isolated from BM (Mohle et al, 1997; Bobik et al, 1998) . Noticeably, VEGFA products in CD34 + culture increased with TPO-induced MK differentiation (Bobik et al, 1998) . Moreover, it was reported that TPO promoted production and release of VEGFA by megakaryocytic precursors in dose-and time-response manners in vitro, especially at hypoxia, which regulates the expression of VEGFA (Casella et al, 2003; Hu et al, 2017) . Taken together, MKs produce and secrete VEGFA, which can be induced by TPO. However, no data about the production and secretion of the four other VEGF family members (VEGFB, VEGFC, VEGFD and PlGF) by MKs have been reported until now, although the VEGFB and VEGFD transcripts have been detected in UT-7/ MPL cells (Gluzmanpoltorak et al, 2001 ). The expression of VEGFR1, VEGFR2 and VEGFR3 on MKs is strictly associated with the stages of differentiation during the development of MKs. It is well known that both VEGFR1 and VEGFR2 are expressed at very low levels in HSCs (Ziegler et al, 1999; Moore et al, 2001; Gerber et al, 2002; Hattori et al, 2002; Casella et al, 2003; Gerber & Ferrara, 2003) , and both VEGFR1 mRNA and VEGFR1 proteins are induced during the initial-intermediate stages of MK differentiation, with a peak expression at days 5 to 7 of culture, and a subsequent decline to lower levels (Casella et al, 2003) . Interestingly, VEGFR2 was expressed in CD41 + progenitors (Hashimoto et al, 2007; Vroling et al, 2007) , indicating that Review VEGFR2 may be expressed in MKPs. However, VEGFR2 was rapidly downregulated soon after the addition of MK-differentiating growth factors, and was re-expressed in the late stage of MK differentiation (Casella et al, 2003) . Another research group also demonstrated that VEGFR2 was expressed at the late differentiation stage of MKs derived from HSCs cultured in serum-free medium in the presence of TPO (Coppola et al, 2006) . Although VEGFR3 transcripts were found in HEL and UT-7/MPL cell lines (Gluzmanpoltorak et al, 2001; Moore et al, 2001) , no data regarding VEGFR3 expression and function in human MKs have been reported. However, VEGFR3 was expressed on mouse MK precursor cells up to the promegakaryoblast stage, but this was lost with the further maturation of MKs (Thiele et al, 2012) . These studies suggest that VEGFR1, VEGFR2 and VEGFR3 are expressed in different developmental stages of MKs, respectively, and may play different roles in megakaryoctopoiesis, respectively (Fig 2) .
Effect of VEGFs/VEGFRs on the development of MKs. The fact that MKs expressed both VEGFs and VEGFRs as well as secreted VEGFs indicated that VEGF autocrine and paracrine loops may be involved in the development of MKs and platelet production. Casella et al (2003) demonstrated that the autocrine/paracrine VEGFA loop enhanced megakaryocytic precursor cell maturation through VEGFR1 (Casella et al, 2003) . In this study, the authors found that the administration of exogenous VEGFA in combination with TPO can slightly increase the DNA ploidy of cultured MKs (mainly 4N MKs). In contrast, blocking VEGFA binding to VEGFR1 with the VEGFR1/Fc (FLT1) fusion protein to capture VEGFA in culture or anti-VEGFR1 neutralizing antibody resulted in a significant reduction in the number of the MKs with lobulated nuclei. Thus, VEGFA may be involved in MK polyploidization and maturation via autocrine or paracrine mode, and VEGFR1 plays an important role in the differentiation and maturation of precursor cells toward MKs (Gerber et al, 2002) . Moreover, it was further demonstrated that the administration of the VEGFA165 isoform in mice led to a significant increase in the number of circulating platelets (Pitchford et al, 2012) . A neutralizing monoclonal antibody with specificity for VEGFR1, but not for VEGFR2, blocked this effect. A selective VEGFR1 agonist (PlGF-2, also termed PGF), rather than VEGFR2 agonist (VEGFE), stimulated an increased number of circulating platelets in vivo, and the effect of PlGF-2 was slightly stronger than that of VEGFA165, which acts on both VEGFR1 and VEGFR2. Interestingly, PlGF-2 increased the maturation of MKs in the BM (mean DNA ploidy enhanced) and CXCR4 expression on the cell surface, but did not alter the absolute number of MKs in the BM and spleen. Moreover, the treatment of MKs with VEGFA165 and PlGF-2 in vivo resulted in their redistribution from the endosteal niches into the vascular niches. Antagonism of CXCR4 inhibited VEGFRl-stimulated MK redistribution in the BM and VEGFA165-induced thrombocytosis. Therefore, these results suggested that VEGFR1-mediated signalling pathways stimulate MK maturation and the upregulation of CXCR4 expression, resulting in the redistribution of MKs in the BM microenvironment and thereby increasing platelet production in vivo (Pitchford et al, 2012) .
VEGFA could also noticeably induce the release of SDF-1a from platelets (Jin et al, 2006) , and SDF-1a regulates MK maturational chemotaxis from the proliferative 'osteoblastic niche' to the 'vascular niche' through the engagement of its specific receptor CXCR4 . However, VEGFA also increases SDF-1a expression in endothelial cells (Salvucci et al, 2002) , which are major components in the vascular niches (Malara et al, 2015) . Moreover, SDF-1a also induces VEGFA production in MKs (Majka et al, 2000) . Therefore, VEGFA may promote megakaryocytopoiesis and thrombopoiesis directly through upregulation of CXCR4 expression in MKs. In addition, it increased both the plasma level and local level of SDF-1a in the BM microenvironment, and a reciprocal regulation may exist between MKs and endothelial cells of the BM environment via VEGFA and SDF-1a (Majka et al, 2000) .
In contrast, the VEGFA-VEGFR2 loop was involved in the proliferation and survival of MKs. By using the TF1-VEGFR2 cell line, which is the granulocyte macrophage-colony-stimulating factor (GM-CSF)-dependent TF1 progenitor cell line with enforced VEGFR2 expression but without other VEGF receptors, such as VEGFR1 or VEGFR3, Coppola et al (2006) found that when the cells were starved of GM-CSF, VEGFA induced cell proliferation and protection against apoptosis, followed by the enhanced expression of megakaryocytic markers. The effects of VEGFA were blocked by the anti-VEGFR2 antibody in the presence of the VEGFR2 inhibitor I, further confirming that VEGFA affects the viability and proliferation by binding to VEGFR2. A further investigation showed that MKs derived from CD34 + HSCs cultured in serum-free medium in the presence of TPO released VEGFA and expressed VEGFR2. The increment of MK differentiation was concomitant with an increase of VEGFA release and VEGFR2 expression. Furthermore, the VEGFR2-blocking antibody decreased the number of MKs with polylobated nuclei and the expression of membrane megakaryocytic markers, suggesting the involvement of VEGFR2 in human megakaryocytopoiesis as well. In addition, Bonsi et al (2005) also found that mRNA transcripts and proteins of VEGFA and VEGFR2 were present on HEL cells, whereas only the VEGFR2 transcript is detectable on another MO7e cell. Meanwhile, autocrine VEGFA could be detected in the HEL cell culture supernatant, but not in the supernatant of the MO7e cell culture. It is noteworthy that HEL cells have a stronger spontaneous proliferative capacity than MO7e cells, suggesting that autocrine VEGFA promotes HEL proliferation (Bonsi et al, 2005) . Taken together, these results indicated that the VEGFA-VEGFR2 axis plays an important role in MK proliferation, survival and differentiation. However, the VEGFC-VEGFR3 loop is involved in the negative regulation of MK development. It has been shown that the specific activation of VEGFR3 by using VEGFC-Cys (a VEGFC mutant), which activates VEGFR3 but not VEGFR2, attenuated the transition to polyploidy of CD41 + cells in the primary BM culture system (Thiele et al, 2012) . The blockade of VEGFR3 consistently promoted polyploidization. In addition, the activation of VEGFR3 in sublethally irradiated mice resulted in a significantly elevated number of CD41 + cells, especially diploid CD41 + cells, in the BM, whereas the number of polyploidy CD41 + cells was significantly reduced (Thiele et al, 2012) . These results demonstrated that the activation of VEGFR3 is involved in a negative regulation of polyploidization of MKs. Taken together, different VEGFs play different roles in different development stages of MKs, whereas the same VEGF plays different roles in different development stages of MKs by binding to different VEGFRs (Fig 2) .
Regulation of the expression of VEGFs/VEGFRs and signalling. As mentioned above, TPO induced the expression and secretion of VEGFA in megakaryocytic cell lines and MKs (Mohle et al, 1997; Bobik et al, 1998; Casella et al, 2003) . Moreover, TPO also increased the level of VEGFA in HSCs (Kirito et al, 2005) . Mechanically, the effect of TPO on HSCs was achieved by decreasing the ubiquitin of the hypoxia inducible factor-1 alpha subunit (HIF-1a, HIF1A), the primary transcriptional regulator of VEGFA expression, leading to stability of the HIF-1a protein (Kirito et al, 2005) . Besides TPO, other cytokines induce HSCs and MKs to produce and secrete VEGFA. It has been shown that SDF-1a activated nuclear factor (NF)-jB, which is one of the PI3K-AKT axis downstream-regulated proteins in normal human megakaryoblastic cells, and induced CD41 + MKs to secrete VEGFA (Majka et al, 2000) . The effect of SDF-1a on the VEGFA secretion of MKs was inhibited by LY294002, indicating that the PI3K-AKT axis was involved in this process (Majka et al, 2000) . Given that NF-jB is involved in the regulation of VEGFA expression (Yoshida et al, 1997) , these results suggest that the PI3K-AKT-NF-jB axis plays a role in the expression and secretion of VEGFA by MKs.
Iron deficiency is associated with reactive thrombocytosis (Schloesser et al, 1965; Kadikoylu et al, 2006; Kuku et al, 2009) . Iron deficiency increased the proportion of cells expressing MKs markers and enhanced pro-platelet formation in culture; meanwhile, in the iron-deficient rats, the expression of endothelial PAS domain protein 1 (HIF2A, EPAS1) was increased in their MKs, and the concentration of VEGFA was higher in the supernatant of iron-deficient culture. It has been shown that HIF2A upregulated VEGFA gene transcription by binding to the hypoxia-response element on the VEGFA promoter (Ema et al, 1997; Flamme et al, 1997; Tian et al, 1997) . Therefore, HIF2A may also upregulate the expression of VEGFA in MKs.
Taken together, several cytokines regulate MKs and their precursor cells to express and secrete VEGFs through different signalling pathways (Fig 3) .
Intracrine loop of VEGFs in megakaryocytes and chemotherapy. Intracrine factors have recently been proposed (Re & Cook, 2008) . A large number of peptide growth factors, hormones, enzymes, DNA binding proteins and other moieties have been shown to act as extracellular signalling agents, while at the same time they apparently have the capability to act in cellular interiors whether it is the interior of the cell that synthesized them, or a target cell that internalized them. In some cases, one product of an intracrine gene acts in the intracellular space, while another is secreted, with or without subsequent internalization by the target cells. These factors have been termed intracrine factors.
VEGFA regulates the survival and repopulation of HSCs through an intracrine loop (Gerber et al, 2002; Kirito et al, 2005) , and also mediates the effect of TPO on the survival of HSCs in the intracrine loop (Kirito et al, 2005) . Consistent with this point of view, hypoxia induces VEGFA expression in the HSCs and enhances HSC numbers as well (Danet et al, 2003) . Boiocchi et al (2011) showed that VEGFR1 and VEGFA were expressed in the same megakaryocytes, and were increased in the megakaryocytes of Ph À MPNs, indicating that a VEGFA/VEGFR1 autocrine or intracrine loop may exist in the normal and malignant MKs. Moreover, VEGFR2 is located in the nucleus of HEL cells with characteristics of megakaryocytic lineage, and it is constitutively phosphorylated (Santos & Dias, 2004) . The treatment of HEL cells with anti-VEGFA monoclonal antibody (Ab 4Á6Á1), which acts in an extracellular compartment, blocked VEGFR2 nuclear translocation and inhibited NF-jB activation. In contrast, the internal VEGFR2-specific inhibitor (VEGFR2 kinase inhibitor I) prevented the constitutive activation of the MAPK/ ERK and PI3K/AKT pathways, and induced apoptosis in the HEL cells although it had little effect on the blockade of VEGFR2 nuclear translocation and the activation of NF-jB. In addition, the externally acting anti-VEGFA monoclonal antibody had little impact on the induction of apoptosis in HEL cells. Thus, the VEGFA-VEGFR2 autocrine and intracrine loops regulate the different MK functions of different signalling pathways; however, the roles of intracrine VEGFs in MK development, MK-associated malignancy, and drug resistance remain unclear. Several studies have shown that intracrine VEGFA-VEGFR2 signalling was required for endothelial cell homeostasis, and the intracrine VEGFA-VEGFR1 loop in tumourassociated endothelial cells predominantly mediated survival (Lee et al, 2007; Zhang et al, 2010) . VEGFA signalling inhibited the constitutive ubiquitination of VEGFR1 via the AKT/ ERK pathway and induced the rapid accumulation of it on endothelial cells, whereas VEGFA signalling via the JNK/cJun pathway induced endocytosis of VEGFR2 (Zhang et al, 2010) , which is essential for the maximal activation of the AKT and ERK1/2 (MAPK3/MAPK1) signal transduction pathways (Smith et al, 2015) , nuclear translocation, and ubiquitination-mediated downregulation of VEGFR2 (Zhang et al, 2010) . Thus, VEGFA signalling controls the intracellular protein levels of VEGFR1 and VEGFR2 through different signalling pathways, respectively. It is important to note that the activation of the MAPK pathway is involved in the polyploidization of MKs (Rojnuckarin et al, 1999; Guerriero et al, 2006) . In addition, the MAPK/ERK and PI3K/AKT pathways are constitutively activated in the HEL cells, and the internal VEGFR2-specific inhibitor prevented this constitutive activation and induced the apoptosis of HEL cells as described above (Santos & Dias, 2004) . Therefore, intracrine VEGF-VEGFR loops may be involved in the regulation of polyploidization and the apoptosis of MKs (Fig 4) .
It was recently reported the VEGFA-VEGFR1 axis acted as an intracrine mode via the apoptosis [caspase-3, cleaved PARP, BAX and survivin (BIRC5)] (Samuel et al, 2011) , survival (AKT) (Bhattacharya et al, 2016) , and proliferation (ERK1/2) (Bhattacharya et al, 2016) pathways to promote the survival of colorectal cancer cells. MKs and platelets noticeably possess a fully functional intrinsic apoptosis pathway (Kile, 2014) . Besides BCL-XL (BCL2L1), MCL1 is required for the growth and development of megakaryocytes (Josefsson et al, 2011; Debrincat et al, 2012; Kodama et al, 2012) . In addition, caspases are involved in some stages of development and the differentiation of MKs (Sarvothaman et al, 2015) . Moreover, the upregulation of pro-survival signalling may contribute to increased MKs and platelet survival in essential thrombocythaemia (ET) and megakaryoblastic leukaemia (Kile, 2014) . Given that the inhibition of VEGFR2 with the internal VEGFR2-specific inhibitor induced apoptosis in HEL cells, the VEGF-VEGFR loops may regulate an intrinsic apoptosis pathway in the megakaryocytic cell line.
Recently, we showed that SP600125 induced the polyploidization of megakaryocytic cell lines by inhibiting the activity of JNK and phosphorylation at Thr421/Ser424 and dephosphorylation at Thr389 of S6K1 , which is also involved in the nocodazole-induced polyploidization of the megakaryocytic cell lines (Ma et al, 2009) . More recently, the data from our laboratory indicated that the level of VEGFR2 was significantly enhanced in the SP600125-induced polyploidy model of megakaryocytic cell lines (unpublished data). VEGFA depletion noticeably impaired the phosphorylation of S6K1 (RPS6KB1) and PRAS40 (AKT1S1), which are downstream of the AKT pathway (Bhattacharya et al, 2016) . Given that VEGFs and VEGFRs are expressed in normal primary MKs and megakaryocytic cell lines as well as in MKs from related haematological disorders and they are involved in survival, proliferation, differentiation and polyploidization, we reasonably proposed that intracrine VEGF/ VEGFR signalling may be implicated in the development of MKs and the pathology of the abnormal megakaryocytopoiesis-related diseases via a similar manner as in solid tumours, and thus might be used as therapeutic targets (Hasselbalch, 2003) (Fig 4) .
Relationship between VEGFs and their receptors and MK-related diseases
The VEGF-VEGFR receptor signal transduction axis is associated with haematological disorders, mainly including myeloproliferative neoplasms (MPNs) (Ni et al, 2006; Panteli et al, 2007; Boiocchi et al, 2011; Medinger et al, 2011) , myelodysplastic syndromes (MDS) (Pruneri et al, 1999; Wimazal et al, 2006) and acute megakaryocytic leukaemia (AML-M7, AMKL) (Ghannadan et al, 2003) (Table I) .
Myeloproliferative neoplasms
The MPNs are a heterogeneous group of malignant haematological disorders that are characterized by the proliferation Fig 3. Cytokines regulate HSCs and MKs to express VEGFs and VEGFRs through different signalling pathways. Thrombopoietin (TPO) induces haematopoietic stem cells (HSCs) and megakaryocytes (MKs) to express and secrete vascular endothelial growth factor A (VEGFA), and stimulates MKs and their precursors to express VEGF receptors (VEGFRs). In HSCs, TPO increases the transcription and expression of VEGFA by inhibiting ubiquitination-mediated degradation of its primary transcriptional regulator, hypoxia-inducible factor 1 alpha (HIF-1a). HIF2A may be involved in this process. Stromal-derived factor 1 (SDF-1) induced the expression and secretion of VEGFA by activating the PI3K-AKT-NF-jB pathway, which is blocked by LY294002. and accumulation of terminally differentiated blood cells of myeloid, erythroid and megakaryocytic origin (Rumi & Cazzola, 2017) . MPNs consist nclude chronic myeloid leukaemia (CML), polycythaemia vera (PV), primary myelofibrosis [PMF; formerly myelofibrosis with myeloid metaplasia (MMM) or idiopathic myelofibrosis (IMF) (Hasselbalch, 2009) ], essential thrombocythaemia (ET; also called primary thrombocytosis), chronic eosinophilia leukaemia and MPN unclassifiable. PV, ET and PMF are classified as classical Philadelphia-negative MPN (Ph À MPNs) (Rumi & Cazzola, 2017) . Angiogenesis and the expression of VEGFA were increased in BCR-ABL1 À MPNs, especially PMFs (Lundberg et al, 2000; Wrobel et al, 2003; Ni et al, 2006; Gianelli et al, 2007) (Table I) . Panteli et al (2007) further showed that VEGFA serum levels of patients with chronic myeloproliferative diseases (cMPDs), including PMF, ET, PV and CML, were significantly increased compared with healthy controls, and the increased levels of VEGFA were significantly correlated with BM microvascular density (MVD). The percentage of VEGFA + cells in the BM positively correlated with serum VEGFA level, although statistically significant differences were not found in the percentages of VEGFA + cells in the patients and the controls. In addition, Krauth et al (2004) found that the degree of VEGFA expression was associated with the stage and progression of CML by using immunohistochemistry staining with an anti-VEGFA antibody on paraffin-embedded BM tissue. In chronic phase CML, the distribution of VEGFA showed a Fig 4. A proposed mechanism involving the regulation of megakaryocyte development and malignant megakaryocytopoiesis by intracrine VEGF-VEGFR loops, which may control the proliferation, survival, apoptosis, and polyploidization of MKs and malignant megakaryocytopoiesis in a similar way as being adopted in solid tumours. Among these, autocrine and paracrine vascular endothelial growth factors (VEGFs) activate the MEK/ERK, PI3K/AKT, and JNK/c-Jun signalling pathways via VEGF receptors (VEGFRs) on the cell surface, and they regulate the intracellular levels of VEGFs and VEGFRs. The JNK/c-Jun pathway induces endocytosis of VEGFR2, which is necessary for maximal activation of AKT and ERK1/2 signal transduction pathways, and the downregulation of VEGFR2 via ubiquitination. SP600125 inhibits the degradation of VEGFR2 and promotes polyploidization. The MEK/ERK1/2 and PI3K/AKT pathways increase the intracellular level of VEGFR1 by inhibiting ubiquitination. MEK/ERK1/2 also promotes the intracellular expression of VEGFs, VEGFR1 and NRP1 directly. Intracrine VEGF-VEGFR loops then regulate proliferation and survival via phosphorylation of AKT and ERK1/2, and enhance survival as well as inhibit BAX expression and cleavage of caspase and PARP. IL6: interleukin 6; KITLG: KIT ligand.
pattern similar to that of normal BM. VEGFA was expressed in myeloid progenitors and megakaryocytes but less abundantly in mature granulomonocytic cells, whereas erythroid cells did not stain positively for VEGFA. In myeloid blast phase CML, myeloblasts expressed substantial amounts of VEGFA. In contrast, little, if any, VEGFA was detected in blast cells in lymphoid blast phase CML. It is important to note that the expression of VEGFA was increased in some patients with the pre-fibrotic form of PMF (Ni et al, 2006) , suggesting that VEGFs may play a role in the early onset of PMF. Thus, VEGFs are important angiogenic factors for cMPDs and are also associated with the pathogenesis of cMPDs. Furthermore, Boiocchi et al (2011) performed an immunohistochemical analysis to determine the expression of the VEGFR1 protein and its relationship with MVD and VEGFA in the BM biopsies from patients with Ph À MPNs. The authors found that the patients with PV and PMF showed an increased MVD compared to ET or normal controls (Table I) . Moreover, the expression of VEGFR1 was also increased, especially in PV and PMF. The VEGFA expression paralleled VEGFR1, and was significantly increased in ET, PV and PMF compared with normal control. In addition, VEGFA expression was even higher in post-polycythaemia myelofibrosis and in the fibrotic stage of PMF than in the non-fibrosis stage of the two diseases. It was shown that the CML-associated fusion oncogene BcrAbl1 induces VEGFA gene expression in growth factor-dependent Ba/F3 cells by promoting the expression of functionally active HIF-1a (Mayerhofer et al, 2002) and in both murine myeloid 32D and MO7e cells transfected with the BCR-ABL1 oncogene (Ebos et al, 2002) . In addition, BCR-ABL1 targeted drug (STI571, imatinib mesylate) reduced VEGFA expression in a dose-dependent manner (Ebos et al, 2002) . Moreover, the treatment of the hypomorphic GATA1
(low) mouse model of PMF with Aplidin (a cyclic depsipeptide) restored the expression of GATA1 and P27KIP1 in GATA1 (low) haematopoietic cells, the proliferation of marrow progenitor cells in vitro, and the maturation of MKs in vivo by reducing TGF-b (TGFB1)/ VEGFA levels released in the microenvironment by immature GATA1 (low) MKs (Verrucci et al, 2010) . Interestingly, thalidomide, acting on the angiogenic process via the VEGFA pathway, has shown initial therapeutic potential in a pilot study for PMF (Piccaluga et al, 2002) . Therefore, targeting VEGFs may be of potential clinical value in MPNs.
Myelodysplastic syndromes (MDS)
Myelodysplastic syndromes (MDS) are clonal stem-cell disorders that predominantly occur in the elderly population. According to the precise classification system of the FrenchAmerican-British (FAB) Cooperative Group, MDS can be classified into five subcategories: refractory anaemia (RA), refractory anaemia with ring sideroblasts (RARS), refractory anaemia with excess of blasts (RAEB), RAEB "in transformation" (RAEB-T), and chronic myelomonocytic leukaemia (CMML) (Bennett et al, 1982) . It has been suggested that VEGFA is an important pathogenic factor, and is believed to be a mediator of leukaemiaassociated angiogenesis, as well as an autocrine growth regulator in MDS (Aguayo et al, 2000 (Aguayo et al, , 2002 Bellamy et al, 2001; Brunner et al, 2002) . Pruneri et al (1999) performed an immunohistochemical analysis of BM MVD and VEGFA expression in biopsy specimens from patients with MDS and found that the MVD in MDS was higher than in the control. In the MDS-FAB subcategories, the MVD in RAEB-T, CMML and the fibrosis subcategories was significantly higher than that in the RA, RARS and RAEB subtypes. In all specimens, VEGFA expression was particularly strong in most of the MKs, but was significantly less prominent in other cell populations, including blasts; there was also no difference in the distribution of VEGFA in the various cellular compartments between MDS and normal BM. Moreover, Wimazal et al (2006) found that VEGFA was expressed in myeloid progenitor cells, immature monocytes, plasma cells and MKs, but not in erythroid cells or mature granulocytes. Furthermore, VEGFA expression was higher in RAEB, RAEB-T and CMML than in RA or RARS or normal controls (Wimazal et al, 2006) . At the same time, MVD was also higher in the RAEB-T and CMML patients than in RA, RARS and normal controls. This difference was due to the increased expression of VEGFA in the immature myeloid cells of RAEB, RAEB-T and CMML. Thus, VEGF expression was associated with the percentages of immature myeloid cells and the FAB category.
Acute myeloid leukaemia (AML)
Acute megakaryocytic leukaemia (AMKL, AML-M7) is a rare subtype of AML, resulting from uncontrolled proliferation of primitive megakaryoblasts without undergoing terminal polyploidization in the BM (Hahn et al, 2016) . It is an independent poor prognostic factor among adults with AML (Giri et al, 2014) . Ghannadan et al (2003) found that VEGFA is mainly expressed in blast cells and MKs in patients with AMKL, suggesting that VEGFA may be involved in the pathology of AMKL.
Conclusion and perspective
An increasing body of evidence indicates that during the development from HSCs to MKs and their progeny platelets, VEGFR1, VEGFR2 and VEGFR3 are expressed at different developmental stages, respectively, and then re-expressed, e.g., VEGFR2. They also play different roles in the commitment, differentiation, proliferation, survival and polyploidization of HSCs/MKs via autocrine, paracrine and/or even intracrine loops. Importantly, VEGFs and VEGFRs are abnormally expressed in MK-related diseases, indicating that they are closely related to these diseases. Thus, targeting of VEGF-VEGFR loops may be of potential therapeutic value. For example, given that administration with small-molecule compounds to induce polyploidy has become a new acute treatment strategy for AMKL (Wen et al, 2012) and MK-driven fibrosis in PMF (Wen et al, 2012) , the inhibition of VEGFR2 downregulation with JNK/c-Jun (JUN) signalling pathway inhibitors (such as SP600125) or upregulation of VEGFR2 to promote polyploidization may rationally pave a new way to screen related drugs. Further studies should shed light on the coordinated effects of VEGFR1, VEGFR2 and VEGFR3 on MK development, particularly endomitosis and polyploidization, as well as their respective downstream signalling mechanisms. Further studies should also clarify the contribution of abnormal VEGF-VEGFR loops to abnormal MK-related diseases.
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